IP Library Granted Patent US 10,905,748
Granted Patent B2
US 10,905,748 · App. 15/954,074 · Granted Feb 2, 2021

Ovotransferrin treatment for the reproductive tract

Inventors: Jamil Talukder (Memphis, TN); Abhijit Ray (Salt Lake City, UT); Daniel J. DuBourdieu (Limerick, ME); Ajay Srivastava (Menomonie, WI); Rajiv Lall (Menomonie, WI)
Assignee: VETS PLUS, INC.
A61K38/40A61K9/0034A61K31/12A61K31/722A61K36/9066A61P15/00A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,748
App. No.
15/954,074
Granted
Feb 2, 2021
Kind
B2
Abstract

A composition and method of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal involves administering ovotransferrin to the reproductive tract of the animal. The ovotransferrin administration protects against and treats reproductive tract infection, while protecting against and treating reproductive tract inflammation such as metritis, and thereby maintains fertility in the animal.

Claims (16)

1. A method of treating and protecting a mammal against infectious metritis comprising administering to the mammal a composition comprising a therapeutically effective amount of ovotransferrin, chitosan, and curcumin, wherein the composition comprises the ovotransferrin, the chitosan, and the curcumin in a ratio of 1:1:1 (ovotransferrin:chitosan:curcumin) by weight.

2. The method of claim 1 wherein the concentration of ovotransferrin in the composition is between 0.1% w/w and 10.0% w/w.

3. The method of claim 1 wherein the concentration of ovotransferrin in the composition is between 1.0% w/w and 5.0% w/w.

4. The method of claim 1 further comprising a therapeutically effective amount of an antimicrobial agent selected from the group consisting of cephalosporin, penicillin, macrolides, quinolones, oxazolidinones, aminoglycosides, and sulfonamides.

5. The method of claim 1 further comprising a therapeutically effective amount of an anti-inflammatory agent.

6. The method of claim 5 wherein the anti-inflammatory agent is selected from the group consisting of garlic, cinnamon, ginger, Roman chamomile, Echinacea, red clover, goldenseal, Vitex (Chaste tree), black pepper and clove.

7. The method of claim 1 wherein the composition is administered in the reproductive tract of the mammal.

8. The method of claim 1 wherein the composition is administered in an infusion having a pH from about 7.5 to about 1.0.

9. The method of claim 1 wherein the administering comprises inserting the composition in the form of a solid bolus into the reproductive tract of the animal.

10. The method of claim 9 wherein the solid bolus comprises the ovotransferrin in an amount from about 1 g to about 30 g.

11. The method of claim 9 wherein the solid bolus comprises the ovotransferrin in an amount from about 1 g to about 14 g.

12. The method of claim 1 wherein the administering comprises:

dissolving a solid bolus comprising the ovotransferrin in a solvent to generate the composition in the form of a liquid; and

administering the liquid into the uterus of the mammal.

13. The method of claim 12 , wherein the solid bolus comprises the ovotransferrin in an amount from about 1 g to about 30 g.

14. The method of claim 12 wherein the solid bolus comprises the ovotransferrin in an amount from about 1 g to about 14 g.

Assignments (3)
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 18, 2022
From: MADISON CAPITAL FUNDING LLC
To: APOGEM CAPITAL LLC, AS SUCCESSOR AGENT
Reel/Frame 059724/0617 →
SECURITY INTEREST Recorded Feb 18, 2022
From: VETS PLUS, INC.
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 059047/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2018
From: DUBOURDIEU, DANIEL J.; LALL, RAJIV; SRIVASTAVA, AJAY; TALUKDER, JAMIL; RAY, ABHIJIT
To: VETS PLUS, INC.
Reel/Frame 045554/0932 →
Continuity (1)
Related Publication 20190314460A1 · Oct 17, 2019